Ideas and Forecasts on Stocks — Denmark — TradingView

Novo Nordisk A/S Class B (NOVO_B) – Bearish Setup | Target: 287 Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis Overview: Based on Arc Cycle Analysis applied to the 2h chart, Novo Nordisk is interacting with the 0.786 Arc within the current Arc Cycle. Price remains centered around this Arc, indicating that directional confirmation has not yet been established.

by Mohamad_Gharib

Novo Nordisk – Bullish Setup | Target: 306.00 #44 NOVO_B Price Outlook: Novo Nordisk Holds Above 1 (100%) Support Arc | Potential Rebound Toward 306.00 Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis Overview: Based on Arc Cycle Analysis applied to the 30m chart, Novo Nordisk is interacting with the 1 (100%) Support Arc within the current Arc Cycle. Price is holding above this Support Arc, suggesting the potential for a bullish rebound toward the next Resistance Arc. Market Outlook Price is holding above the 1 (100%) Support Arc, indi

by Mohamad_Gharib

Is Novo breaking out of a falling trend channel?In 2024, Novo formed a head–shoulder pattern with a breakdown at the end of September. Since then, the stock has been moving within a falling trend channel until now. On September 18 this year, the stock broke above the trend channel by 6–7% on increased volume. It has since pulled back to test the upper line of the channel and is now moving up again. There is resistance around 390. If the stock breaks significantly above this level with rising volume, it will be clearly technically positive.

The Iron Leviathan: A Structural Analysis of Cyclical Crossroads The ocean does not care for your spreadsheet formulas, nor does it weep when your capital sinks into the deep. Five thousand winters ago, we read the stars and the flight of birds to survive the treacherous trade routes. Today, we read the candlestick charts of Maersk. This is an ancient empire built on modern steel, sitting at a fascinating cosmic crossroads where fundamental value meets brutal macroeconomic tides. To understand this enterprise, an investor must look beyond short term price ac

Technical and Fundamental Assessment of Genmab Technical Analysis Genmab has been in an upward trend since the beginning of April 2025. The trend is only partly supported by the moving averages (MA) and is weakened by a declining RSI-21. The price is currently below or near the lower edge of a red Ichimoku cloud and is trading in the lower part of the trend channel. Volume balance has been close to neutral over the past six months. Volume is an important independent indicator, as it is not based on an interpretation of price. The stock ha

Finding support at $213 Broke long term trend, find the next support around $213.

Novo Nordisk made some wild moves. What's next? In this video I explain why I was looking at an accumulation schematic, but also why this could've been a distribution as well. I also show a bit of NYSE:NIO to explain how to approach pictures vs reality. Again, not going to much into depth as for me taking these video's is something I have to get used to. Please leave a comment with feedback.

14:49

NOVO NORDISK finishing an accumulation pattern As the title says, and you'll be able to see in the chart: It seems like NYSE:NVO is finishing up an accumulation here. Spring setting in right now. For better confirmation wait for some weekly closes above bottom of range here.

Novo 1h AB=CD to gap close Novo keeps making succesful ab=cd's at the moment. Smaller ones turning into partt of bigger etc. Right now an even bigger one would take it to a possible channel low, a "failed turning point" and gap close. I'm definitely watching this closely!

Novo Nordisk about to finish accumulation range?As the title says. Looks like NYSE:NVO is finishing up an relative small accumulation range. Question is whether the spring-test is done here or not. Sometimes there's a big push and retrace to create a test. Sometimes something that resembles current PA can be enough. Let's see how it develops. But expecting continuation up on the higher timeframe. Breakout and retest of downwards trend (descending channel) would be a big sign.

Pandora (PNDORA) - Reversal Play OMXCOP:PNDORA My Thesis in 4 Bullets: The market fears $112/oz silver costs, but the CFO just confirmed they are >75% hedged for 2026 (likely locked near ~$35/oz).They will also have time to adjust jewelry`s silver to metal ratio. Valuation Dislocation: Pandora trades at ~7.5x P/E while peers like Signet and Richemont trade at ~26x. A simple reversion to 12x doubles the stock. The "India" Call Option: The EU-India Free Trade Agreement (FTA) is a hidden catalyst. It eliminates tariffs on ge

$NVO — another upside breakout today. Still holding the full pos NYSE:NVO — another upside breakout today. Still holding the full position, now with a large open profit. The Danish primary listing of Novo Nordisk, OMXCOP:NOVO_B , is now trading in clear air. The 460 DKK area looks like the most logical swing target, which aligns slightly above my $70 zone on the US listing.

by Swing_Trader_Saan

NOVO: The Pawn That Refused to Fall – Triangle Breakout Imminent The Thesis: Novo Nordisk (NOVO_B / NVO) just survived the ultimate geopolitical stress test. With the recent threats regarding US tariffs on Denmark (the "Greenland leverage"), Novo was the perfect pawn in a high-stakes negotiation. The market panic briefly flushed the price down to test critical support, but the rebound was instant and violent. This tells me one thing: There are no sellers left. The underlying demand is massive. Technical Setup: The First Consolidation We are currently witn

by enakocapital

Bearish divergence After initial breakout, first sign of RSI divergence. This is combined with double top, and huge volu not able to push price higher tells me it is time to book 50% of the profit.

by yash_gurjar_07

Novo Nordisk - Inverse H&S after a long bear market Im going long here with a tight stop loss. Thinking it´s time for a reversal. I pointed out which levels im looking at.

by Mr_Anonymous_Investor

Possible buy signal forming after inverse head and shoulders?NSIS (Novonesis) has formed an Inverse Head and Shoulders (IHS) formation from August 20 to November 6 this year. The IHS is a reversal formation. NSIS broke out of a falling trend on September 30. The question now is whether we will get a buy signal from a significant breakout above the neckline — i.e., more than 3% with increased volume. We haven’t seen that yet. Such a move would also represent a clear breakout above the resistance at 415. Price momentum indicators, including RSI 21, are p

Play (continued): Reversal caused by positive news Triggers: 1) Positive news - Better than expected orders Analysis/Observations: 1) In a channel trending up 2) Slightly higher volume in channel 3) In between control points 4) Channel at 200 between March and August 2026 Portfolio: 1) Entered at 113.5 in July 2025

Safe play for the next five years?Using the historical data on the log proves the lifetime trend for this stock. I believe this is a good buy for the long run.

$ORSTED Orsted has been in a persistent downtrend since its peak, without ever breaking the pattern. Technical analysis has long warned investors to stay away from the stock. The company has now filed for a $9 billion restructuring plan, driven by its oversized offshore wind projects. The plan is backed both by the Danish state (which owns 50%) and external investors. Shareholders of all sizes have been devastated.

by StockTradingTips

H+H International A/S | Chart & Forecast Summary Key Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set Up 3. Break & Retest Set Up Notes On Session # H+H International A/S - Double Formation * (Trending Attitude)) - *0.5 - *Retest & Entry - *25EMA | Subdivision 1 * (Range Allocation)) | No Size Up - *Retest Area | Completed Survey * 95bars, 2893d | Date Range Method - *(Downtrend Argument)) - Triple Formation * (P1)) / (P2)) & (P3)) | Subdivision 2 * Monthly Time Frame | Trend Settings Condition | Subdivision 3 - (Hypothesis

by UnknownUnicorn87383881

Novonesis daily reversal?Measured move / 3-point channel to test of failed symmetry zone. Might take 1/3 off around 445 depending on PA. I might add to the position if the bearish ab=cd at 431 fails and I'll be looking to take the loss if it drops below 400. Haven't used harmonic patterns for a long time, but this does resemble a 5-0 pattern if I'm not mistaken?

NovoNordisk, LT dirt cheap | GLP-1 a misunderstood growth market Novo Nordisk stock has lost quite some weight since the release of Eli lilly's drug Zepbound and Mounjaro and since the rise of compounded, or generic copycat GLP-1 alternatives. The growth of the company has slown down a bit, but the overall GLP-1 market growth is still impressive and misunderstood. Both Lilly and NVO have become some of the cheapest PEG stocks in the markets and compettitors, of which most known, Hims en hers health also took a slice of growth of this market by telehealth GLP-

by Asset_Sniper

If you want to buy NOVO.....A follower asked for my opinion on this stock which he said many are shorting this and asks if he should be a contrarian instead. I do not own this stock and has no intention to at this moment but just looking at the chart, here's my 2cents : 1) price has fallen by 70+% from the peak from June 2024 (more than 12 months of bearish moves) 2) price is still in the downward channel and no reversal pattern is in sight 3) How will Donald Trump's tariffs hit these pharma companies down the road re

Novo Nordisk, generational buying opportunity? Novo Nordisk is currently experiencing one of the largest drawdowns in its history, primarily triggered by a downward revision of guidance for FY25 and FY26. Focusing strictly on technical analysis: For the first time, the monthly 200 EMA is serving as a key support level for Novo Nordisk - an area the stock has never approached in its previous history. The long-term trendline, originating in 1989 and successfully tested three times since 1995, remains intact and is being approached on